LEXETTE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Lexette, and what generic alternatives are available?

Lexette is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-seven patent family members in fourteen countries.

The generic ingredient in LEXETTE is halobetasol propionate. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the halobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lexette

A generic version of LEXETTE was approved as halobetasol propionate by FOUGERA PHARMS on December 16^th, 2004.

Try a Trial

Summary for LEXETTE

International Patents:	27
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for LEXETTE
What excipients (inactive ingredients) are in LEXETTE?	LEXETTE excipients list
DailyMed Link:	LEXETTE at DailyMed

Drug patent expirations by year for LEXETTE

Recent Clinical Trials for LEXETTE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Skin Sciences, PLLC	Phase 4

See all LEXETTE clinical trials

Pharmacology for LEXETTE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for LEXETTE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXETTE	Topical Foam	halobetasol propionate	0.05%	210566	1	2021-01-28

US Patents and Regulatory Information for LEXETTE

LEXETTE is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting LEXETTE

Halobetasol foam composition and method of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Corticosteroid containing foam compositions and method of manufacture thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER

FDA Regulatory Exclusivity protecting LEXETTE

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	LEXETTE	halobetasol propionate	AEROSOL, FOAM;TOPICAL	210566-001	May 24, 2018		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Mayne Pharma	LEXETTE	halobetasol propionate	AEROSOL, FOAM;TOPICAL	210566-001	May 24, 2018		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial			Y	⤷ Try a Trial
Mayne Pharma	LEXETTE	halobetasol propionate	AEROSOL, FOAM;TOPICAL	210566-001	May 24, 2018		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LEXETTE

See the table below for patents covering LEXETTE around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Spain	2770325		⤷ Try a Trial
Eurasian Patent Organization	201891352	ВСПЕНИВАЮЩИЕСЯ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ КОРТИКОСТЕРОИД, И СПОСОБ ИХ ПРОИЗВОДСТВА	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2017103719		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration